Clinical Pipeline
Chronic Wound
| Stage | Timeline | ||
|---|---|---|---|
| KV23c | Calciphylaxis | Phase 3 | Projected Start Q2 2022 End 2024 |
| ” “ | ” “ | Phase 2 | Projected Start Q4 2022 End 2023 |
| ” “ | Venous Leg Ulcer | RWE | Projected Start Q3 2025 End 2027 |
| KV27d | Diabetic foot ulcer | RWE | Planning Phase 2 Projected Start Q2 2023 |
| KV32a | Autoimmune ulcers | RWE | Planning Phase 2 Projected Start Q2 2024 |
Acute Wound
| Stage | Timeline | ||
|---|---|---|---|
| KV52p | Calciphylaxis | RWE | Planning Phase 1 Start Q3 2023 |
| KV02b | Burns (2nd degree+) | Exploratory |
Mucous Membrane Wound
| Stage | Timeline | ||
|---|---|---|---|
| KVgin | Gingivitis | Exploratory | |
| KV07v | Vaginal & peri-anal | RWE |
Non-prescription
| Stage | Timeline | ||
|---|---|---|---|
| VinSan | Burns (1st degree) | RWE | Safety and Stability Projected Start Q4 2022 |
Other
| Stage | Timeline | ||
|---|---|---|---|
| KV10ra | Rheumatoid Arthritis | RWE |
Exploratory / RWE Preclinical or Real World Evidence
Phase 1 / 2 Safety & Efficacy
Phase 3 Clinical Relevance